Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Molecular Partners AG before investing.

In this article, we go over a few key elements for understanding Molecular Partners AG’s stock price such as:

• Molecular Partners AG’s current stock price and volume
• Why Molecular Partners AG’s stock price changed recently
• Upgrades and downgrades for MOLN from analysts
• MOLN’s stock price momentum as measured by its relative strength

About Molecular Partners AG (MOLN)

Before we jump into Molecular Partners AG’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Want to learn more about Molecular Partners AG’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Molecular Partners AG.

Molecular Partners AG’s Stock Price as of Market Close

As of June 04, 2026, 1:49 PM, CST, Molecular Partners AG’s stock price was $3.930.

Molecular Partners AG is down 2.48% from its previous closing price of $4.030.

During the last market session, Molecular Partners AG’s stock traded between $3.930 and $3.950. Currently, there are approximately 46.75 million shares outstanding for Molecular Partners AG.

Molecular Partners AG’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Molecular Partners AG Stock Price History

Molecular Partners AG’s (MOLN) price is currently down 6.43% so far this month.

During the month of June, Molecular Partners AG’s stock price has reached a high of $4.120 and a low of $3.780.

Over the last year, Molecular Partners AG has hit prices as high as $5.360 and as low as $3.410. Year to date, Molecular Partners AG’s stock is down 9.83%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Molecular Partners AG Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 03, 2026, there was 1 analyst who downgraded Molecular Partners AG’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Molecular Partners AG’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Molecular Partners AG’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Molecular Partners AG (MOLN) by visiting AAII Stock Evaluator.

Relative Price Strength of Molecular Partners AG

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 03, 2026, Molecular Partners AG has a weighted four-quarter relative price strength of -8.59%, which translates to a Momentum Score of 32 and is considered to be Weak.

Want to learn more about how Molecular Partners AG is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Molecular Partners AG Stock Price: Bottom Line

As of June 4, 2026, Molecular Partners AG’s stock price is $3.930, which is down 2.48% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Molecular Partners AG stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.